Dazopride

Dazopride is an antiemetic agent. In Vivo: Dazopride (0.3 mg/kg) produces significant enhancement of gastric evacuation and is approximately six times more potent than metoclopramide in gastric evacuation assay. Dazopride (0.3-10.0 mg/kg, i.v.) produces a dose-related increase in antral motility primarily by increasing the amplitude of antral contractions in three conscious dogs. Dazopride significantly reduces the emetic frequency from that of the control group^[1]. Dazopride (5 mg/kg, i.p.) antagonises the tetralin-induced emesis in all animals, but fails to antagonise the response at 0.25-2.5 mg/kg. Dazopride fails to modify cisplatin-induced emesis at 0.1 mg/kg (i.v,) although a larger dose of 1.0 mg/kg abolishes or attenuates the response and 5.0 mg/kg of dazopride antagonises the development ofemesis in all animals^[2].